FASN-IN-7
FASN-IN-7 is a potent and orally active inhibitor of human Fatty Acid Synthase (FASN) . FASN-IN-7 shows enzyme inhibition on full length FASN and the FASN KR domain with IC50 values of 28 and 54 nM. FASN-IN-7 effectively inhibits proliferation of multiple cancer cell types. FASN-IN-7 increases malonyl-CoA levels and decreases palmitate levels in tumor tissues[1].
Product Specifications
CAS Number
1579514-16-1
UNSPSC
12352005
Target
Fatty Acid Synthase (FASN)
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C1N(C[C@H]2CN(C(C3CC3)=O)CC2)C(C4=CC=C(C5=CC=C(C6=CN(C)N=C6)C=C5)C=C4)=NC71CC7
Molecular Formula
C30H31N5O2
Molecular Weight
493.60
References & Citations
[1]Lu T, et al. Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy. Bioorg Med Chem Lett. 2018;28 (12) :2159-2164.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680304-500 1x 500 µL
CD106 / VCAM1 (B-K9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940525-500 1x 500 µL
CD63 (MX-49.129.5), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040296-100 1x 100 µL
Blood Group Antigen B (CD173) (HEB-20), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741594-500 1x 500 µL
CD22 / BL-CAM (B-Cell Marker) (RFB4), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740226-100 1x 100 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details